Vaccine News and Research

Latest Vaccine News and Research

Inovio first quarter total revenue decreases to $1.7 million

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2012.

10 May 2012

One in six cancer cases worldwide related to preventable or curable infections

New research shows that one in six cancers - amounting to two million a year globally - are caused by largely treatable or preventable infections.

9 May 2012

Grade 12 researcher wins top honors at 2012 Sanofi BioGENEius Challenge Canada

An Ontario girl, 16, who invented a disease-fighting, anti-aging compound using nano-particles from trees, won top national honours today in the 2012 Sanofi BioGENEius Challenge Canada.

9 May 2012

Free whooping cough vaccine cut concerns experts

Heath experts are concerned that parents and carers of newborn babies will stop getting the whooping cough vaccine after the state government cut its free immunisation program in the midst of a fatal epidemic.

9 May 2012

BioDiem announces new vaccine research collaboration with French-based VIVALIS

Australian vaccine development company BioDiem Ltd (ASX: BDM) today announced that it has begun a research collaboration with France-based VIVALIS (Euronext code: VLS), a biopharmaceutical company with expertise in vaccine production technologies.

9 May 2012

Basser Research Center to focus on treatment and prevention of inherited cancers

A $25 million gift to the University of Pennsylvania from alumni Mindy and Jon Gray will establish a center focused on the treatment and prevention of cancers associated with hereditary BRCA mutations.

9 May 2012

iBio receives U.S. patent for iBioModulator platform

iBio, Inc. today announced issuance of a US patent covering compositions of matter and methods of use of modified lichenase B polypeptides comprising the Company's iBioModulator platform.

9 May 2012

Advaxis commences enrollment in ADXS-HPV Phase 1/2 study for head and neck cancer

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that two patients have been enrolled into REALISTIC, a Phase 1/2 study being sponsored by Cancer Research UK (CRUK) to investigate the use of ADXS-HPV for the treatment of HPV positive head and neck cancer. HPV is associated with 40-70% of head and neck cancers.

8 May 2012

Certain males at higher risk of infection after receiving experimental HIV vaccine

A long-term follow-up analysis of participants in the Step Study, an international HIV-vaccine trial, has confirmed that certain subgroups of male study participants were at higher risk of becoming infected after receiving the experimental vaccine compared to those who received a placebo.

8 May 2012

Researchers discover potential way to develop universal flu vaccines

University of British Columbia researchers have found a potential way to develop universal flu vaccines and eliminate the need for seasonal flu vaccinations.

8 May 2012

Cholera strain in Haiti evolving, CDC reports

"The cholera strain in Haiti is evolving, researchers reported Thursday, a sign that it may be taking deeper root in the nation less than two years after it appeared and killed thousands of people," the Associated Press/USA Today reports.

8 May 2012

Scientists make important discovery about internal programming of B cells

Scientists at The Scripps Research Institute have made an important discovery about the internal programming of B cells, the immune cells that make antibodies against infections. The finding opens the way for the development of vaccines that can work more efficiently and hints at therapies for conditions in which B cells cause harm—such as the autoimmune disease lupus erythymatosus, severe allergies, and B-cell lymphomas.

8 May 2012

Meningitis B vaccine on the horizon

Meningitis B is particularly dangerous for children, leading to 120 deaths in the UK every year. There are around 1,200 new cases of meningitis B every year. Around 1 in 10 victims die and another 15 per cent are left with permanent disabilities - often limbs have to be amputated due to blood poisoning. The infection causes inflammation of the membranes surrounding the spinal cord and brain. Symptoms include a severe headache, vomiting, a rash, sensitivity to light and a stiff neck.

8 May 2012

Children's vaccine for pneumococcal disease does not offer full protection

The vaccine given to children to immunise against serious pneumococcal disease does not offer full protection, reveals research from the Sahlgrenska Academy at the University of Gothenburg, Sweden, finding that the number of cases diagnosed has tripled over the past 50 years.

7 May 2012

School-based health centers highly effective in delivering comprehensive care

New research from the University of Colorado School of Medicine shows that school-based health centers are highly effective in delivering comprehensive care, especially vaccines to adolescents.

7 May 2012

Intellect Neurosciences announces two new programs in Alzheimer's disease development pipeline

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases, today announced two new programs in its Alzheimer's disease development pipeline. The new programs are based on two antibodies that target early neurotoxic forms of tau protein, which Intellect intends to develop for therapeutic and diagnostic uses.

7 May 2012

Fluidigm offers unrestricted sales of digital PCR and non-invasive prenatal diagnostics

Fluidigm Corporation today announced that it can now offer unrestricted sales of its digital PCR and other advanced technology to customers interested in pursuing research and product development into the prenatal health and non-invasive prenatal diagnostics fields, as well as other fields.

7 May 2012

NovaDigm reports positive data from Phase 1 NDV-3 vaccine program

NovaDigm Therapeutics, a company developing innovative vaccines for fungal and bacterial infections, today announced the presentation of positive data for its NDV-3 vaccine program in a second Phase 1 study.

7 May 2012

Data from Idera IMO-8400 preclinical studies for SLE and psoriasis presented at AAI meeting

Idera Pharmaceuticals, Inc. today announced data from preclinical studies of IMO-8400, demonstrating a novel mechanism of action that may be applicable to the treatment of systemic lupus erythematosus (SLE) and psoriasis. IMO-8400 is an inhibitor of specific Toll-like receptors (TLRs).

7 May 2012

Accentia, Johns Hopkins co-host meeting with prospective clinical trial investigators at AAN meeting

Accentia Biopharmaceuticals, Inc. today announced that the Company and leading physicians from Johns Hopkins University co-hosted a meeting with prospective clinical trial investigators at the recent American Academy of Neurology (AAN) Annual Meeting in New Orleans.

7 May 2012